Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Advanced Enzyme Technologies Limited (ADVENZYMES.NS)
Thane, IN
Advanced Enzyme Technologies Limited, headquartered in Thane, India, is a global company engaged in the research, development, manufacturing, and marketing of enzymes and probiotics. Its operations span India, the United States, Asia, and Europe. The company's diverse enzyme offerings cater to human healthcare, animal nutrition, and an extensive range of food processing sectors, including fruit and vegetable, baking, brewing, malting, grain, protein modification, yeast, dairy, and oils/fats processing, as well as various specialty applications. Beyond food-related uses, it also supplies industrial enzymes for non-food industries like textile processing, leather, pulp and paper production, detergents and cleaning aids, biofuels, and biocatalysis. Founded in 1957, the company was previously known as Advanced Biochemicals Limited before changing its name to Advanced Enzyme Technologies Limited in 2005.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.14% | +5.59% | +25.67% | +22.18% | +13.04% | +23.74% | +26.12% | +29.03% | -19.07% | +58.73% | +58.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+17.1% ★ Q1'26: +21.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+28.7% ★ Q1'26: +62.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+15.1% Q1'26: +22.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+25.3% ★ Q1'26: +26.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+14.0% ★ Q1'26: +15.9% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.13× ★ Q1'26: 0.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.30B
est: 3.31B (-0.4%)
|
3.88B
est: 4.00B (-2.9%)
|
4.18B
est: 4.20B (-0.4%)
|
4.42B
est: 4.52B (-2.2%)
|
5.00B
est: 5.10B (-1.8%)
|
5.29B
est: 5.29B (-0.1%)
|
5.41B
est: 5.41B (0.0%)
|
6.23B
est: 5.91B (+5.5%)
|
6.37B
est: 6.54B (-2.6%)
|
7.30B
7.30B – 7.30B
+11.6% YoY
|
8.54B
8.54B – 8.54B
+16.9% YoY
|
9.97B
9.97B – 9.97B
+16.8% YoY
|
| EBITDA |
1.54B
est: 1.28B (+20.6%)
|
1.62B
est: 1.77B (-8.2%)
|
1.88B
est: 1.62B (+15.9%)
|
2.09B
est: 1.75B (+18.9%)
|
2.41B
est: 2.10B (+14.9%)
|
2.09B
est: 2.38B (-12.3%)
|
1.79B
est: 2.73B (-34.4%)
|
2.27B
est: 3.10B (-26.8%)
|
2.27B
est: 3.03B (-25.0%)
|
2.82B
2.82B – 2.82B
-7.0% YoY
|
3.29B
3.29B – 3.29B
+16.9% YoY
|
3.85B
3.85B – 3.85B
+16.8% YoY
|
| EBIT |
1.41B
est: 1.08B (+30.3%)
|
1.44B
est: 1.69B (-15.0%)
|
1.66B
est: 1.62B (+2.5%)
|
1.82B
est: 1.61B (+12.5%)
|
2.12B
est: 1.86B (+13.5%)
|
1.74B
est: 2.12B (-17.8%)
|
1.44B
est: 2.42B (-40.5%)
|
1.92B
est: 2.75B (-30.3%)
|
1.91B
est: 3.14B (-39.2%)
|
2.38B
2.38B – 2.38B
-24.3% YoY
|
2.78B
2.78B – 2.78B
+16.9% YoY
|
3.25B
3.25B – 3.25B
+16.8% YoY
|
| Net Income |
906.49M
est: 1.03B (-12.0%)
|
900.55M
est: 1.12B (-19.2%)
|
1.11B
est: 1.00B (+11.0%)
|
1.29B
est: 1.11B (+16.0%)
|
1.46B
est: 1.36B (+7.0%)
|
1.20B
est: 1.55B (-22.7%)
|
1.06B
est: 1.77B (-40.2%)
|
1.33B
est: 2.01B (-33.8%)
|
1.31B
est: 1.46B (-10.0%)
|
1.52B
1.52B – 1.52B
+4.6% YoY
|
1.74B
1.74B – 1.74B
+14.0% YoY
|
2.06B
2.06B – 2.06B
+18.7% YoY
|
| SGA |
167.19M
est: 389.74M (-57.1%)
|
217.46M
est: 879.71M (-75.3%)
|
223.24M
est: 1.24B (-82.0%)
|
219.80M
est: 1.23B (-82.2%)
|
898.46M
est: 1.01B (-11.3%)
|
1.10B
est: 1.15B (-4.3%)
|
379.08M
est: 1.31B (-71.1%)
|
397.22M
est: 1.50B (-73.4%)
|
426.09M
est: 769.36M (-44.6%)
|
858.98M
858.98M – 858.98M
+11.6% YoY
|
1.00B
1.00B – 1.00B
+16.9% YoY
|
1.17B
1.17B – 1.17B
+16.8% YoY
|
| EPS |
8.27
est: 9.19 (-10.0%)
|
8.07
est: 9.03 (-10.6%)
|
9.95
est: 11.80 (-15.7%)
|
11.58
est: 12.86 (-9.9%)
|
13.07
est: 13.80 (-5.3%)
|
10.70
est: 10.70 (+0.0%)
|
9.45
est: 11.40 (-17.1%)
|
11.92
est: 10.70 (+11.4%)
|
11.70
est: 13.00 (-10.0%)
|
13.60
13.60 – 13.60
+4.6% YoY
|
15.50
15.50 – 15.50
+14.0% YoY
|
18.40
18.40 – 18.40
+18.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.01% | 6.3K | 0.54% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Beni Prasad Rauka | Chief Financial Officer | — | male |
| Bhaskar Manolkar | General Manager of Human Resources & Administration | — | male |
| Dipak Roda | Senior Vice President of Marketing & Business Development | — | male |
| Harshad Doshi | Chief Financial Officer & Chief Operating Officer of US Subsidiaries | — | male |
| Martina Doering | MD & Head of Business Development - evoxx technologies GmbH | — | female |
| Michael Puls | MD & Head of Research and Development - evoxx technologies GmbH | — | — |
| Ronak Saraf | Investor Relations Manager | — | male |
| Sanjay Prakash Basantani | Company Secretary, Head of Legal & Compliance Officer | — | male |
| Satish Pagar | Plant Manager & Head of Operations - Sinnar | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADVENZYMES.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
